- ►diabetesjournals.org Y Miyazaki, A Mahankali, M Matsuda, L Glass, … - Diabetes Care, 2001 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 23 diabetic patients (age 30–70
years, BMI < 36 kg/m 2 ) who were being treated with a stable dose of
sulfonylurea were randomly assigned to receive either placebo (n = 11) or ... Cited by 273 - Related articles - BL Direct - All 7 versions
- Free from Publisher Y Miyazaki, M Matsuda, RA DeFronzo - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—Patients treated with 7.5 or 15 mg/day of pioglitazone had no change
in fasting plasma glucose (FPG) and fasting plasma insulin (FPI) concentrations
or in plasma glucose (PG) and insulin concentrations during the OGTT. ... Cited by 133 - Related articles - BL Direct - All 6 versions
MS Kipnes, A Krosnick, MS Rendell, JW Egan … - The American journal of medicine, 2001 - Elsevier RESULTS: Patients receiving pioglitazone + sulfonylurea had significant (P
<0.05) decreases from baseline in HbA 1C and fasting plasma glucose levels
compared with patients treated with placebo + sulfonylurea. As compared ... Cited by 235 - Related articles - BL Direct - All 8 versions
- ►endojournals.org Y Miyazaki, A Mahankali, M Matsuda, S … - Journal of Clinical Endocrinology & Metabolism, 2002 - Endocrine Soc We examined the effect of pioglitazone on abdominal fat distribution to
elucidate the mechanisms via which pioglitazone improves insulin resistance in
patients with type 2 diabetes mellitus. Thirteen type 2 diabetic patients ... Cited by 334 - Related articles - BL Direct - All 8 versions
Y Miyazaki, L Glass, C Triplitt, M Matsuda, … - Diabetologia, 2001 - Springer The thiazolidinediones represent a new class of insu- lin sensitizing agents for
the treatment of Type II (non-insulin-dependent) diabetes mellitus. The origi-
nal drug in this class, troglitazone, has been shown to ameliorate insulin ... Cited by 205 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org [PDF] S Aronoff, S Rosenblatt, S Braithwaite, JW … - Diabetes Care, 2000 - Am Diabetes Assoc Pioglitazone hydrochloride, a thiazo- lidinedione compound, is a new ther-
apeutic agent for the treatment of type 2 diabetes that reduces insulin
resistance by enhancing insulin action in skeletal muscle, liver, and ... Cited by 243 - Related articles - All 6 versions
J Patel, RJ Anderson, EB Rappaport… - Diabetes Obesity and Metabolism, 1999 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 147 - Related articles - BL Direct - All 3 versions
- Free from Publisher MA Khan, JV St Peter, JL Xue - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—A total of 127 patients completed follow-up: 67 individuals in the PIO
group (32 women, 35 men) and 60 individuals in the ROSI group (33 women, 27
men). There were no significant differences in gender mix, age, weight, ... Cited by 231 - Related articles - BL Direct - All 6 versions
J Rosenstock, D Einhorn, K Hershon, NB … - International journal of clinical practice(Esher), 2002 - cat.inist.fr The glycaemic and lipid effects of treatment with pioglitazone in combination
with a stable insulin regimen were evaluated in patients with type 2 diabetes.
Patients(n= 566) receiving stable insulin regimens for ≥ 30 days yet who ... Cited by 111 - Related articles - All 4 versions
